Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Objectives:
Primary:
Safety and tolerability of therapy with daratumumab in a cohort of patients with metastatic
renal cell carcinoma and a cohort of patients with muscle invasive bladder cancer.
Secondary:
1A. To assess the proportion of patients who achieve pathological CR with daratumumab in
patients with muscle invasive bladder cancer.
1B. To assess the objective response rate (ORR) to daratumumab in patients with metastatic
renal cell carcinoma.
2. To assess the progression free survival for patients with metastatic renal cell carcinoma
receiving Daratumumab.